Table 2.
Treatment effect on efficacy outcomes according to background diuretic therapy
| Primary composite | No diuretic (n = 683) |
Non-loop diuretic (n = 769) |
<40 mga (n = 1811) |
40 mga (n = 1902) |
>40 mga (n = 1098) |
P interaction (diuretic use/type) | P interaction (diuretic dose) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Placebo | Dapagliflozin | Placebo | Dapagliflozin | Placebo | Dapagliflozin | Placebo | Dapagliflozin | Placebo | Dapagliflozin | |||
| Event rate | 7.3 | 5.3 | 3.9 | 4.2 | 8.3 | 6.4 | 9.8 | 7.9 | 18.1 | 15.3 | ||
| HR (95% CI) | 0.74 (0.48–1.12) | 1.08 (0.67–1.74) | 0.76 (0.60–0.97) | 0.81 (0.66–1.00) | 0.84 (0.68, 1.04) | 0.64 | 0.57 | |||||
| CV death | ||||||||||||
| Event rate | 3.3 | 2.6 | 1.6 | 2.8 | 3.2 | 2.6 | 4.0 | 3.3 | 6.3 | 5.5 | ||
| HR (95% CI) | 0.77 (0.42–1.39) | 1.82 (0.95–3.50) | 0.83 (0.57–1.19) | 0.82 (0.60–1.13) | HR = 0.86 (0.62, 1.20) | 0.31 | 0.75 | |||||
| HF event | ||||||||||||
| Event rate | 4.7 | 3.4 | 2.7 | 1.9 | 5.9 | 4.8 | 6.9 | 5.3 | 15.4 | 12.6 | ||
| HR (95% CI) | 0.71 (0.42–1.20) | 0.69 (0.36–1.31) | 0.81 (0.61–1.07) | 0.77 (0.60–0.99) | 0.82 (0.65, 1.03) | 0.99 | 0.63 | |||||
| HFH | ||||||||||||
| Event rate | 3.8 | 2.5 | 2.5 | 1.5 | 5.2 | 4.3 | 6.3 | 4.8 | 14.7 | 11.2 | ||
| HR (95% CI) | 0.65 (0.36–1.18) | 0.61 (0.31–1.22) | 0.83 (0.62–1.11) | 0.77 (0.59–1.00) | 0.76 (0.60, 0.97) | 0.61 | 0.91 | |||||
| All-cause death | ||||||||||||
| Event rate | 5.8 | 5.4 | 4.3 | 4.9 | 6.2 | 6.4 | 9.2 | 7.2 | 10.7 | 11.1 | ||
| HR (95% CI) | 0.92 (0.60–1.41) | 1.14 (0.73–1.76) | 1.04 (0.81–1.33) | 0.78 (0.63–0.97) | 1.03 (0.81, 1.32) | 0.22 | 0.69 | |||||
| KCCQ-TSS 1 month |
78.7 ± 20.2 | 77.5 ± 19.6 | 80.2 ± 17.9 | 80.4 ± 18.1 | 77.9 ± 19.0 | 80.5 ± 16.9 | 74.4 ± 19.7 | 75.2 ± 20.5 | 69.3 ± 22.5 | 71.9 ± 22.4 | ||
| Difference | 1.7 (−0.7 TO 4.1) | 1.4 (−0.6 to 3.5) | 2.0 (0.7–3.3) | 0.6 (−1.0 to 2.2) | 4.0 (1.7, 6.3) | 0.08 | 0.13 | |||||
| KCCQ-TSS 8 months |
80.1 ± 18.8 | 82.0 ± 17.4 | 79.6 ± 19.7 | 81.5 ± 17.6 | 78.8 ± 19.7 | 81.6 ± 16.8 | 75.0 ± 21.3 | 77.1 ± 20.0 | 72.5 ± 21.8 | 74.7 ± 21.1 | ||
| Difference | 3.5 (0.9–6.2) | 3.5 (0.9–6.1) | 2.0 (0.4–3.6) | 1.7 (−0.3 to 3.7) | 2.9 (0.1, 5.7) | 0.88 | 0.78 | |||||
Dose in furosemide equivalents.
CI, confidence interval; CV, cardiovascular; HF, heart failure, HFH, heart failure hospitalization; HR, hazard ratio; KCCQ-TSS, Kansas City Cardiomyopathy Questionnaire total symptom score.